Compounds > 3-(4-(4-phenyl-1,2,3,6-tetrahydropyridyl-1)-butyl)indole
Page last updated: 2024-09-03

3-(4-(4-phenyl-1,2,3,6-tetrahydropyridyl-1)-butyl)indole and n-n-propylnorapomorphine

3-(4-(4-phenyl-1,2,3,6-tetrahydropyridyl-1)-butyl)indole has been researched along with n-n-propylnorapomorphine in 1 studies

Compound Research Comparison

Studies
(3-(4-(4-phenyl-1,2,3,6-tetrahydropyridyl-1)-butyl)indole)		Trials
(3-(4-(4-phenyl-1,2,3,6-tetrahydropyridyl-1)-butyl)indole)		Recent Studies (post-2010)
(3-(4-(4-phenyl-1,2,3,6-tetrahydropyridyl-1)-butyl)indole)		Studies
(n-n-propylnorapomorphine)		Trials
(n-n-propylnorapomorphine)		Recent Studies (post-2010) (n-n-propylnorapomorphine)
1810274412

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bohmaker, K; Friedhoff, AJ; Goldstein, M; Meller, E; Schweitzer, JW1

Other Studies

1 other study(ies) available for 3-(4-(4-phenyl-1,2,3,6-tetrahydropyridyl-1)-butyl)indole and n-n-propylnorapomorphine

ArticleYear
Chronic haloperidol does not alter agonist affinity for dopamine receptors in vitro.
    European journal of pharmacology, 1985, Mar-12, Volume: 109, Issue:3

    Topics: Animals; Apomorphine; Binding, Competitive; Corpus Striatum; Haloperidol; Indoles; Male; Rats; Rats, Inbred Strains; Receptors, Dopamine; Receptors, Dopamine D2; Spiperone

1985